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Abstract 
 
Objectives: To investigate the relationship between fetal congenital heart defects (CHD) and 
placental perfusion assessed by uterine artery pulsatility index (UtA-PI) in relation to 
development of preeclampsia (PE). 
 
Methods: This was a prospective screening study in singleton pregnancies at 19-24 weeks’ 
gestation. Transvaginal ultrasound was used to measure the UtA-PI and the values were 
converted into multiples of the normal median (MoM). Median MoM values in pregnancies 
with fetuses with isolated major CHD were compared to those without CHD in relation to 
development of PE. 
 
Results: The 91,407 singleton pregnancies fulfilling the entry criteria included 206 (0.23%) 
with isolated major fetal CHD and 91,201 without CHD. The prevalence of PE was 4.4% in 
those with CHD and 2.7% in those without CHD (RR 1.6, 95% CI 0.84-3.04; p=0.150); the 
respective values for preterm-PE, with delivery at <37 weeks’ gestation, were 2.4% and 
0.7%, (RR 3.4, 95% CI 1.42-8.09; p=0.006). In the total population, the median UtA-PI MoM 
was significantly higher in those that developed PE compared to those without PE (1.22, IQR 
0.94-1.57 vs. 1.00, IQR 0.84-1.19; p<0.0001) and in the PE group the median UtA-PI MoM 
was inversely related to gestational age at delivery (r=-0.458; p<0.0001). The same pattern 
of inverse relationship between UtA-PI MoM and gestational age at delivery with PE was 
observed in pregnancies with and without CHD, but in the CHD group, compared to those 
without CHD, UtA-PI was significantly higher both in pregnancies with and in those without 
PE. 
 
Conclusions: In both pregnancies with and without fetal CHD that develop PE impedance to 
flow in the uterine arteries is increased and this increase is particularly marked in those with 
preterm-PE. The prevalence of preterm-PE is more than 3 times higher in pregnancies with 
than without fetal major CHD and the prevalence of major CHD in pregnancies with preterm-
PE is also more than 3 times higher than in those without PE. However, >97% of 
pregnancies with fetal CHD do not develop preterm-PE and >99% of pregnancies with 
preterm-PE are not associated with fetal CHD.  
 
 
Introduction 
 
A common pathophysiological mechanism for maternal preeclampsia (PE) and fetal 
congenital heart defects (CHD) is suggested by the findings that first, in both conditions 
there is evidence of impaired placental angiogenesis and second, there is epidemiological 
evidence of an association between PE and CHD. In pregnancies that develop PE the 
maternal serum level of the proangiogenic placental growth factor (PLGF) at 11-13 weeks’ 
gestation is reduced and the deviation from normal is greater for early than late PE.1-3 A 
study of 68 pregnancies with isolated major fetal CHD and 340 normal controls at 11-13 
weeks’ gestation reported that in the CHD group, compared to the controls, maternal serum 
levels of PLGF were lower.4 This finding was confirmed in a prospective screening study in 
50,094 singleton pregnancies at 11-13 weeks, which demonstrated that in the group of 196 
with isolated major fetal CHD serum PLGF was reduced.5  A study of 1,942,072 neonates 
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born in Canada between 1989 and 2012, reported that the prevalence of CHD was higher in 
infants from pregnancies with than without PE and this was particularly so for early-PE <34 
weeks’ gestation (RR 5.5, 95% CI 5.0-6.2).6 A study of 914,703 singleton births without 
chromosomal abnormalities in Norway between 1994 and 2009, reported that the prevalence 
of severe CHD was higher in infants of pregnancies with than without PE and this was 
particularly so for early-PE (RR 2.8, 95% CI 1.8-4.4).7 A study of 1,972,857 singleton births 
without chromosomal abnormalities in Denmark between 1978 and 2011, reported that in the 
presence of fetal CHD there is a 7-fold increase of risk of early-PE.8  
 
In PE, particularly preterm-PE, there is evidence from Doppler studies of impaired 
uteroplacental perfusion, reflected in increased uterine artery pulsatility index (UtA-PI).2,9-11 
The objective of this study is to investigate further the association between fetal CHD and 
maternal PE by examining second-trimester UtA-PI in pregnancies with and without major 
CDH. 
 
 
Methods 
 
Study population 
This was a prospective observational study in women with singleton pregnancies attending 
for a routine hospital visit at 19+0 - 24+6 weeks’ gestation at King’s College Hospital, London 
or Medway Maritime Hospital, Gillingham, UK, between April 2006 and October 2017. This 
visit, included recording of maternal demographic characteristics and medical history, 
measurement of maternal weight and height, ultrasound examination for fetal anatomy and 
growth and measurement of the left and right UtA-PI by transvaginal color Doppler 
ultrasound and calculation of the mean value of the two arteries.12 The ultrasound 
examination of the fetus was carried out transabdominally and included a sweep through the 
heart in transverse plane for assessment of the four-chamber view, outflow tracts and three 
vessel view of the heart and great vessels. The scans were carried out by sonographers who 
had obtained the appropriate Fetal Medicine Foundation certificate of competence in 
ultrasound scanning and all cases of suspected fetal abnormalities were examined by a fetal 
medicine specialist. Likewise, all cases of suspected fetal cardiac defect were examined by 
a fetal cardiologist. Gestational age was determined by the measurement of fetal crown-
rump length at 11-13 weeks or the fetal head circumference at 19-24 weeks.13,14 The women 
gave written informed consent to participate in the study, which was approved by the NHS 
Research Ethics Committee. 
 
All neonates were examined by a pediatrician. Prenatal and neonatal findings were recorded 
in computerised databases. Data on pregnancy outcome from women who booked for 
obstetric care in our hospitals but delivered in other hospitals were obtained either from the 
maternity computerised records in these hospitals or the general medical practitioners of the 
women. 
 
The obstetric records of all women with pre-existing or pregnancy associated hypertension 
were examined to determine if the condition was chronic hypertension, PE or non-proteinuric 
gestational hypertension. The definition of PE was that of the International Society for the 
Study of Hypertension in Pregnancy.15 Preterm-PE and early-E were defined as delivery with 
PE at <37 and <34 weeks’ gestation, respectively. 
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Inclusion and exclusion criteria 
In this study we compared the measurements of UtA-PI in pregnancies with and without 
major fetal cardiac defects. The inclusion criterion for the control group was pregnancy 
delivering a non-malformed live birth or stillbirth at >24 weeks’ gestation. We excluded 
pregnancies with aneuploidies and major fetal abnormalities. In the group with cardiac 
defects we included all cases with major cardiac defects diagnosed by pediatric cardiologists 
either antenatally and / or in the neonatal period. Abnormalities suspected antenatally but 
not confirmed in the neonates were not included. In contrast, the prenatal diagnosis in cases 
of stillbirths were assumed to be correct because in these cases post mortem examination 
was not performed systematically. We excluded all aneuploidies and non-cardiac defects 
diagnosed prenatally or in the neonatal period. The following fetal cardiac defects were not 
included: first, ventricular septal defects not requiring surgery, second, right aortic arch, 
persistent left superior vena cava and aberrant right subclavian artery because these are 
variants of normal rather than true defects and third, ventricular aneurysms or cardiac 
tumors developing during the second and third trimesters of pregnancy. 
 
 
Patient characteristics 
Recording of patient characteristics included maternal age, racial origin (White, Black, South 
Asian, East Asian and mixed), method of conception (spontaneous or assisted conception 
requiring the use of ovulation drugs or in vitro fertilization), cigarette smoking during 
pregnancy, medical history of chronic hypertension, diabetes mellitus, systemic lupus 
erythematosus or anti-phospholipid syndrome, family history of PE in the mother of the 
patient and obstetric history including parity (parous or nulliparous if no previous 
pregnancies at or after 24 weeks), previous pregnancy with PE, and interval in years 
between birth of the last child and estimated date of conception of the current pregnancy. 
Maternal weight and height were measured and the BMI was calculated. 
 
Statistical analysis 
Comparison of the maternal characteristics between the outcome groups was by the χ2-
square test or Fisher’s exact test for categorical variables and Mann-Whitney U-test for 
continuous variables, respectively. The measured values of UtA-PI were expressed as a 
multiple of the normal median (MoM) after adjustment for those characteristics that provide a 
substantial contribution to their log10 transformed value.16 Median UtA-PI MoM values were 
compared between outcome groups by Mann Whitney U-test. Regression analysis was used 
to examine the association of UtA-PI MoM with gestational age at delivery. 
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp, 2013) was used for the data analyses. 
 
 
Results 
 
The 91,407 singleton pregnancies fulfilling the entry criteria included 206 (0.23%) with 
isolated major fetal CHD and 91,201 without CHD. The median gestational age at ultrasound 
examination was 22.1 (IQR 20.6, 22.6) weeks. The maternal and pregnancy characteristics 
in the outcome groups are compared in Table 1. There were no significant differences 
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between the groups in maternal characteristics and medical history, but in the CHD group 
the gestational age at delivery was lower and the incidence of preterm-PE was higher. 
 
The major cardiac defects included tetralogy of Fallot (n=50), transposition of the great 
arteries (n=29), coarctation of the aorta (n=27), pulmonary atresia or stenosis (n=22), 
atrioventricular septal defect (n=19), left atrial isomerism (n=11), hypoplastic left or right 
heart (n=10), tricuspid atresia or stenosis (n=8), double outlet right ventricle (n=6), aortic 
stenosis (n=5), large ventricular septal defect requiring surgery (n=4), common arterial trunk 
(n=3), and complex (n=12). 
 
The prevalence of preeclampsia (PE) was 4.4% (9 of 206) in those with CHD and 2.7% 
(2,490 of 91,201) in those without CHD (RR 1.6, 95% CI 0.84-3.04; p=0.150); the respective 
values for preterm-PE were 2.4% (5 of 206) and 0.7% (653 of 91,201), (RR 3.4, 95% CI 
1.42-8.09; p=0.006). Therefore, the prevalence of major CHD was 0.36% (9 of 2,499) in 
pregnancies with PE and 0.22% (197 of 88,908) in those without PE (RR 1.6, 95% CI 0.83-
3.17; p=0.153); the respective values for preterm-PE were 0.76% (5 of 658) and 0.22% (201 
of 90,749) (RR 3.4, 95% CI 1.42-8.31; p=0.006). 
 
In the total population, the median UtA-PI MoM was significantly higher in those that 
developed PE compared to those without PE (1.22, IQR 0.94-1.57 vs. 1.00, IQR 0.84-1.19; 
p<0.0001) and in the PE group the median UtA-PI MoM was inversely related to gestational 
age at delivery (r=-0.458; p<0.0001). The same pattern was observed in pregnancies with 
and without CHD, but in the CHD group, compared to those without CHD, UtA-PI was 
significantly higher both in pregnancies with and in those without PE (Table 2). 
 
 
 
Discussion 
 
Main findings of the study 
 
The findings of the study, that the prevalence of preterm-PE is more than 3 times higher in 
pregnancies with than without major fetal CHD and the prevalence of major CHD in 
pregnancies with preterm-PE is also more than 3 times higher than in those without PE, are 
consistent with those of large epidemiological studies. However, the study has also 
highlighted that >97% of pregnancies with fetal CHD do not develop preterm-PE and >99% 
of pregnancies with preterm-PE are not associated with fetal CHD. There is coincidence of 
both CHD and preterm-PE in about 5 per 100,000 pregnancies. 
 
The epidemiological studies highlighting the association between fetal CHD and PE reported 
that the increased risk was mainly affecting the rate of early-PE with delivery at <34 weeks’ 
gestation.6-8 However, the incidence of such early-PE in the general population is very low 
(0.2 - 0.3%)7,8 and even with a 7-fold increase in the case of fetal CHD8 the expected 
incidence in such cases would be only 1-2%. 
  
We found that both in pregnancies with and in those without CHD that develop PE 
impedance to flow in the uterine arteries is increased and this increase is particularly marked 
in those with preterm-PE. Several previous studies have reported that in pregnancies that 
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develop PE, UtA-PI MoM is increased in the first, second and third trimesters and that the 
increase is inversely related to the gestational age at which delivery is undertaken for 
maternal and / or fetal indications.2,3,9-11,17-24 These Doppler ultrasound findings have been 
interpreted as supportive evidence for the results of histological studies that PE is associated 
with impairment of the physiological process of trophoblastic invasion of the maternal spiral 
arteries and their conversion from narrow muscular vessels to dilated non-muscular 
channels. 25-27 
 
In a small number of pregnancies there is coincidence of CHD and impaired placentation 
which is reflected in low first-trimester serum PLGF4,5 and high second-trimester UtA-PI. The 
pathophysiological mechanism for such an association is uncertain. There is emerging 
evidence that the placenta and fetal heart share several developmental pathways and they 
consequently share a common vulnerability to genetic defects and early environmental 
insults, a phenomenon known as the heart-placenta axis.28 There is also evidence from 
animal studies that placental insufficiency can cause CHD, but what is not so evident is how 
the interaction between genetic defects and placental insufficiency alters heart development 
and how that interaction contributes to CHD.29 In our study there were no significant 
differences in maternal characteristics between the CHD and non-CHD groups but in the 
CHD group, even in the absence of PE, UtA-PI was increased; it is therefore possible that in 
a small number of cases there is an underlying genetic abnormality that affects both the 
development of the heart and that of the placenta and in such cases reduced placental 
perfusion with consequent hypoxia could result in CHD. 
 
 
 
 
 
Strengths and limitations 
The strengths of this study are first, screening of a large population of pregnant women 
attending for routine assessment at 19-24 weeks’ gestation, second, routine screening for 
cardiac defects based on a standardized protocol, examination of all cases with suspected 
CHD by a fetal cardiologist and examination of all neonates by a pediatrician, and third, use 
of a specific methodology and appropriately trained doctors to obtain measurements of UtA-
PI and expression of the values as MoMs after adjustment for factors that affect the 
measurements. A limitation of the study is that although we examined 91,407 pregnancies, 
the number of isolated major cardiac defects was small; nevertheless the sample size was 
sufficient to demonstrate that the association between fetal CHD and preterm-PE was 
significant. We did not investigate minor cardiac defects, such as ventricular septal defects 
not requiring surgery, because prenatal detection during routine screening is likely to 
underestimate the true incidence of the defect. 
 
Comparison with other studies 
In a previous screening study at 11-13 weeks’ gestation there was no significant difference 
in median UtA-PI MoM between 196 pregnancies with and 49,898 without major fetal CHD, 
but in that study the values in pregnancies with PE were not reported.5  Another study at 18-
37 weeks’ gestation, involving 65 pregnancies with isolated major CHD that did not develop 
PE and 204 uncomplicated pregnancies delivering phenotypically normal neonates, reported 
no significant differences in UtA-PI between the two groups.30  
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Implications for clinical practice 
In the presence of CHD there is a 3-4 fold increase in risk of preterm-PE and such increase 
is similar to that of other risk factors, such as Black racial origin, family history of PE and 
diabetes mellitus, but less than the 13-fold increase in women with chronic hypertension and 
the 6-fold increase in those with previous PE.9 In screening for preterm-PE by the competing 
risks model the finding of isolated major CHD, observed in about 0.2% of pregnancies, could 
be included in the algorithm for calculation of the prior risk which is then combined with the 
results of biomarkers for estimation of the patient-specific posterior risk.32 This would be 
particularly useful in the assessment of risk for preterm-PE because the high-risk group 
would benefit from prophylactic use of aspirin.33 In the case of second-trimester diagnosis of 
CHD the pregnancies would benefit from close monitoring for development of PE, which 
would be useful in deciding the best time and method of delivery. 
 
Conclusion 
In both pregnancies with and without fetal CHD that develop PE impedance to flow in the 
uterine arteries is increased and this increase is particularly marked in those with preterm-
PE. The prevalence of preterm-PE is more than 3 times higher in pregnancies with than 
without fetal major CHD and the prevalence of major CHD in pregnancies with preterm-PE is 
also more than 3 times higher than in those without PE.  
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Table 1. Maternal and pregnancy characteristics of the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Calculated for parous women 
a
 = p <0.0001, 
b
 = p <0.01,  
PE = preeclampsia; IQR = interquartile range; SLE = systemic erythematosus lupus; APS = 
antiphospholipid syndrome. 
Maternal characteristics 
No cardiac defects 
(n=91,201) 
Cardiac defects 
(n=206) 
Age in years, median (IQR) 30.8 (27.3-34.7) 31.4 (25.9-34.7) 
Weight in Kg, median (IQR) 71.4 (63.8-82.0) 70.0 (60.8-82.0) 
Height in cm, median (IQR) 165 (160-169) 165 (160-169) 
Racial origin   
   White, n (%) 65,076 (71.4) 156 (75.7) 
   Black, n (%) 18,005 (19.7) 33 (16.0) 
   South Asian, n (%) 3,871 (4.2) 9 (4.4) 
   East Asian, n (%) 1,837 (2.0) 4 (1.9) 
   Mixed, n (%) 2,412 (2.6) 4 (1.9) 
Conception   
   Natural, n (%) 88,232 (96.7) 197 (95.6) 
   Use of ovulation drugs, n (%) 822 (0.9) 4 (1.9) 
   In vitro fertilization, n (%) 2,147 (2.4) 5 (2.4) 
Cigarette smoking, n (%) 8,866 (9.7) 16 (7.8) 
Chronic hypertension, n (%) 1,246 (1.4) 0 (0.0) 
SLE / APS, n (%) 183 (0.2) 0 
Diabetes mellitus, n (%) 790 (0.9) 1 (0.5) 
Parity   
  Nulliparous, n (%) 44,303 (48.6) 97 (47.1) 
   Parous no previous PE, n (%) 44,089 (48.3) 103 (50.0) 
   Parous previous PE, n (%) 2,809 (3.1) 6 (2.9) 
Family history of PE, n (%) 3,541 (3.9) 3 (1.5) 
Pregnancy interval in years, median (IQR)* 3.0 (2.0-5.1) 3.0 (2.4-4.0) 
Gestation at delivery in weeks, median (IQR) 40.0 (39.0-40.9) 38.6 (37.4-39.3) 
a
 
Preeclampsia   
   Any 2,490 (2.7) 9 (4.4)  
   Delivery at <37 w, n (%) 653 (0.7) 5 (2.4) 
b
 
   Delivery at <34 w, n (%) 300 (0.3) 1 (0.7) 
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Table 2. Median uterine artery pulsatility index multiple of the median, with interquartile range in the 
pregnancies with and without congenital heart defects. 
 
 
Outcome 
Heart defects  (n=206) No heart defects (n=91,201) 
P value 
n UtA-PI MoM (IQR) n UtA-PI MoM (IQR) 
Preeclampsia      
  All 9 1.82 (1.25-2.03) 2,490 1.22 (0.94-1.57) 0.017 
  Preterm 5 1.88 (1.35-2.03) 653 1.59 (1.28-1.93) 0.482 
  Early 1 1.87 (1.77-1.87) 300 1.74 (1.47-2.07) 0.721 
No preeclampsia 197 1.05 (0.88-1.31) 88,711 1.00 (0.84-1.19) 0.001 
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